High-Resolution Melting Analysis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global High-Resolution Melting Analysis Market is projected to expand from USD 2.59 Billion in 2025 to USD 4.54 Billion by 2031, reflecting a CAGR of 9.81%. High-Resolution Melting Analysis functions as a specialized technique for detecting genetic variations in nucleic acid sequences by observing fluorescence shifts in double-stranded DNA binding dyes during thermal denaturation. Market growth is primarily driven by the method's speed and cost-effectiveness compared to sequencing, rendering it ideal for extensive genotyping and methylation research. Additionally, the increasing burden of infectious diseases and genetic conditions fuels the need for such accessible diagnostic tools. As reported by MedTech Europe in 2024, the European medical technology sector was valued at approximately 170 billion Euros, with in vitro diagnostics leading the market, highlighting the strong industrial ecosystem supporting these analytical methods.

Conversely, the market encounters substantial hurdles due to the decreasing costs and broader availability of Next Generation Sequencing. This rival technology provides enhanced sensitivity and multiplexing abilities for identifying rare variants, often surpassing the resolution capabilities of melting analysis in intricate clinical scenarios. Consequently, laboratories that require exhaustive genomic profiling may prefer sequencing platforms over melting analysis, a trend that could constrain the latter's growth within advanced diagnostic environments.

Market Drivers

The increasing prevalence of infectious diseases and genetic disorders acts as a major driver for the Global High-Resolution Melting Analysis Market, creating a demand for fast and affordable mutation scanning capabilities. As these health burdens increase, clinical laboratories are turning to melting analysis for the efficient identification of pathogens and single nucleotide polymorphisms, avoiding the complexity associated with sequencing. For example, the American Cancer Society's 'Cancer Facts & Figures 2025' from January 2025 projected over 2 million new cancer diagnoses in the United States for the year, emphasizing the urgent need for accessible genomic profiling. This demand is further intensified by the spread of communicable diseases; the Centers for Disease Control and Prevention reported in September 2025 that there were over 2.2 million recorded sexually transmitted infections in 2024, underscoring the vast diagnostic scale required in public health.

Furthermore, technological improvements in thermal cycling and qPCR instrumentation play a crucial role in market growth by optimizing workflow efficiency and sensitivity. Modern systems feature enhanced temperature uniformity and advanced algorithms that simplify high-throughput screening and the analysis of complex melt curves. These innovations lower entry barriers, enabling a wider array of research and diagnostic facilities to implement the technology for genotyping and methylation studies. The strength of this industry is reflected in financial results; for instance, Thermo Fisher Scientific reported in January 2025 that their fourth-quarter revenue rose by 5% to $11.40 billion, a performance attributed in part to the continued adoption of their sophisticated diagnostic and analytical instruments.

Market Challenges

A major obstacle for the Global High-Resolution Melting Analysis Market is the falling cost and growing accessibility of Next Generation Sequencing. This competing approach offers superior multiplexing and sensitivity, allowing for the concurrent detection of rare mutations and multiple genetic variants, achieving performance standards that melting analysis frequently fails to match. As clinical needs evolve toward comprehensive genomic profiling, laboratories often favor sequencing platforms that offer profound insights into complex genetic structures, thereby diminishing their dependence on melting analysis for high-complexity diagnostic applications.

This shift is especially evident in oncology and genetic disorder management, where precise variant classification is critical. For example, the American Cancer Society estimated that the number of new cancer cases in the United States in 2024 would exceed 2 million for the first time. The rising burden of such complex pathologies fuels the necessity for the exhaustive genomic data provided by sequencing, which directly restricts the broader adoption of melting analysis technologies within advanced clinical diagnostic settings.

Market Trends

The widespread adoption of CRISPR/Cas9 technology has established a trend wherein High-Resolution Melting is increasingly employed as a rapid, cost-efficient screening method to detect mutations and verify gene edits in plants and cell lines prior to utilizing costly sequencing. As research efforts intensify, laboratories depend on this technique to streamline the validation of guide RNA efficacy and confirm genetic alterations. This heightened development activity is significant; in February 2025, CRISPR Therapeutics reported a strong cash position of roughly $1.9 billion in their 'Fourth Quarter and Full Year 2024 Financial Results', capital which supports their extensive gene-edited therapy pipeline and drives the usage of mutation screening instruments and reagents.

Concurrently, the market is seeing substantial growth within the food safety and agricultural sectors, where HRM is essential for seed quality testing, botanical authentication, and high-throughput crop genotyping. This approach is superseding traditional methods because of its capacity to quickly differentiate closely related plant cultivars and identify supply chain adulteration without the need for intricate post-PCR processing. The magnitude of this testing demand is illustrated by the financial results of major service providers; Eurofins Scientific reported record total revenues of €6.95 billion in their January 2025 '2024 Full Year Results', a success largely driven by the continued organic expansion of their Food and Feed Testing division in North America.

Key Players Profiled in the High-Resolution Melting Analysis Market

• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories, Inc.
• F. Hoffman-La Roche Ltd.
• Illumina, Inc.
• Agilent Technologies, Inc.
• BIOMeRIEUX Inc.
• Meridian Bioscience, Inc.
• Qiagen GmbH
• Azura Genomics Inc.
• Canon Medical Systems Corporation

Report Scope

In this report, the Global High-Resolution Melting Analysis Market has been segmented into the following categories:

High-Resolution Melting Analysis Market, by Product and Service:

• Instruments
• Reagents and Consumables
• Software
• Services

High-Resolution Melting Analysis Market, by Application:

• SNP Genotyping
• Mutation Discovery
• Species Identification
• Pathogen Identification
• Epigenetics
• Others

High-Resolution Melting Analysis Market, by End User:

• Research Laboratories and Academic Institutes
• Hospitals and Diagnostic Centers
• Pharmaceutical and Biotechnology Companies
• Others

High-Resolution Melting Analysis Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global High-Resolution Melting Analysis Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.